GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Cyclically Adjusted Price-to-FCF

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Cyclically Adjusted Price-to-FCF : 21.19 (As of Apr. 28, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Ligand Pharmaceuticals Cyclically Adjusted Price-to-FCF?

As of today (2024-04-28), Ligand Pharmaceuticals's current share price is $70.57. Ligand Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $3.33. Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 21.19.

The historical rank and industry rank for Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LGND' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.58   Med: 40.51   Max: 1014.6
Current: 21.19

During the past years, Ligand Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 1014.60. The lowest was 13.58. And the median was 40.51.

LGND's Cyclically Adjusted Price-to-FCF is ranked better than
83.17% of 101 companies
in the Biotechnology industry
Industry Median: 54.65 vs LGND: 21.19

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $-2.415. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $3.33 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ligand Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.31 33.65 39.94 19.99 21.45

Ligand Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.99 20.66 20.16 16.41 21.45

Competitive Comparison of Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Ligand Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=70.57/3.33
=21.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Ligand Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.415/129.4194*129.4194
=-2.415

Current CPI (Dec. 2023) = 129.4194.

Ligand Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.045 99.695 0.058
201406 0.182 100.560 0.234
201409 0.162 100.428 0.209
201412 0.369 99.070 0.482
201503 0.209 99.621 0.272
201506 0.262 100.684 0.337
201509 0.427 100.392 0.550
201512 0.548 99.792 0.711
201603 0.333 100.470 0.429
201606 -0.398 101.688 -0.507
201609 0.710 101.861 0.902
201612 1.230 101.863 1.563
201703 0.835 102.862 1.051
201706 0.447 103.349 0.560
201709 1.174 104.136 1.459
201712 1.297 104.011 1.614
201803 2.450 105.290 3.011
201806 3.014 106.317 3.669
201809 1.126 106.507 1.368
201812 1.418 105.998 1.731
201903 2.127 107.251 2.567
201906 -3.122 108.070 -3.739
201909 -0.330 108.329 -0.394
201912 -0.408 108.420 -0.487
202003 1.024 108.902 1.217
202006 1.461 108.767 1.738
202009 0.793 109.815 0.935
202012 0.029 109.897 0.034
202103 0.426 111.754 0.493
202106 1.106 114.631 1.249
202109 1.065 115.734 1.191
202112 1.461 117.630 1.607
202203 2.802 121.301 2.990
202206 0.310 125.017 0.321
202209 0.887 125.227 0.917
202212 3.096 125.222 3.200
202303 1.754 127.348 1.783
202306 -0.016 128.729 -0.016
202309 0.412 129.860 0.411
202312 -2.415 129.419 -2.415

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ligand Pharmaceuticals  (NAS:LGND) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ligand Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Headlines

From GuruFocus

Ligand Provides Highlights from its Investor and Analyst Day Event

By Business Wire Business Wire 12-13-2022

Ligand to Report Fourth Quarter Financial Results on February 22

By Business Wire Business Wire 02-06-2023

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

By Business Wire Business Wire 04-24-2023